TY - JOUR
T1 - Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
AU - Driessen, Julia
AU - Kersten, Marie José
AU - on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)
AU - Visser, Lydia
AU - van den Berg, Anke
AU - Tonino, Sanne H.
AU - Zijlstra, Josée M.
AU - Lugtenburg, Pieternella J.
AU - Morschhauser, Franck
AU - Hutchings, Martin
AU - Amorim, Sandy
AU - Gastinne, Thomas
AU - Nijland, Marcel
AU - Zwezerijnen, Gerben J.C.
AU - Boellaard, Ronald
AU - de Vet, Henrica C.W.
AU - Arens, Anne I.J.
AU - Valkema, Roelf
AU - Liu, Roberto D.K.
AU - Drees, Esther E.E.
AU - de Jong, Daphne
AU - Plattel, Wouter J.
AU - Diepstra, Arjan
N1 - Funding Information:
This work was supported by research funding from Takeda.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12
Y1 - 2022/12
N2 - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
AB - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
UR - http://www.scopus.com/inward/record.url?scp=85140062604&partnerID=8YFLogxK
U2 - 10.1038/s41375-022-01717-8
DO - 10.1038/s41375-022-01717-8
M3 - Article
C2 - 36241696
AN - SCOPUS:85140062604
SN - 0887-6924
VL - 36
SP - 2853
EP - 2862
JO - Leukemia
JF - Leukemia
IS - 12
ER -
